                               SEQUENCE LISTING

<110> NATIONAL UNIVERSITY OF SINGAPORE
      DSO NATIONAL LABORATORIES
 
<120> EPSTEIN-BARR VIRUS LMP2 SPECIFIC ANTIBODY AND USES THEREOF

<130> 97520-948339

<140>
<141>

<150> 62/016,536
<151> 2014-06-24

<160> 39    

<170> PatentIn version 3.5

<210> 1
<211> 9
<212> PRT
<213> Epstein-Barr virus

<400> 1
Cys Leu Gly Gly Leu Leu Thr Met Val 
1               5                   


<210> 2
<211> 9
<212> PRT
<213> Epstein-Barr virus

<400> 2
Tyr Leu Leu Glu Met Leu Trp Arg Leu 
1               5                   


<210> 3
<211> 9
<212> PRT
<213> Epstein-Barr virus

<400> 3
Phe Met Val Phe Leu Gln Thr His Ile 
1               5                   


<210> 4
<211> 9
<212> PRT
<213> Cytomegalovirus

<400> 4
Asn Leu Val Pro Met Val Ala Thr Val 
1               5                   


<210> 5
<211> 9
<212> PRT
<213> Cytomegalovirus

<400> 5
Ile Leu Ala Arg Asn Leu Val Pro Met 
1               5                   


<210> 6
<211> 9
<212> PRT
<213> Cytomegalovirus

<400> 6
Val Leu Glu Glu Thr Ser Val Met Leu 
1               5                   


<210> 7
<211> 9
<212> PRT
<213> Cytomegalovirus

<400> 7
Val Leu Ala Glu Leu Val Lys Gln Ile 
1               5                   


<210> 8
<211> 10
<212> PRT
<213> Cytomegalovirus

<400> 8
Tyr Ile Leu Gly Ala Asp Pro Leu Arg Val 
1               5                   10  


<210> 9
<211> 9
<212> PRT
<213> Hepatitis B virus

<400> 9
Phe Leu Pro Ser Asp Phe Phe Pro Ser 
1               5                   


<210> 10
<211> 10
<212> PRT
<213> Bacillus Calmette-Guerin

<400> 10
Phe Ile Tyr Ala Gly Ser Leu Ser Ala Leu 
1               5                   10  


<210> 11
<211> 9
<212> PRT
<213> Influenza A virus 

<400> 11
Gly Ile Leu Gly Phe Val Phe Thr Leu 
1               5                   


<210> 12
<211> 9
<212> PRT
<213> Hepatitis B virus

<400> 12
Phe Leu Leu Thr Arg Ile Leu Thr Ile 
1               5                   


<210> 13
<211> 9
<212> PRT
<213> Human immunodeficiency virus

<400> 13
Ile Leu Lys Glu Pro Val His Gly Val 
1               5                   


<210> 14
<211> 9
<212> PRT
<213> Human immunodeficiency virus

<400> 14
Lys Leu Thr Pro Leu Cys Val Thr Leu 
1               5                   


<210> 15
<211> 9
<212> PRT
<213> Human immunodeficiency virus

<400> 15
Ser Leu Tyr Asn Thr Ile Ala Val Leu 
1               5                   


<210> 16
<211> 9
<212> PRT
<213> Cytomegalovirus

<400> 16
Asn Leu Pro Val Met Val Ala Thr Val 
1               5                   


<210> 17
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 17
Ala Leu Gly Gly Leu Leu Thr Met Val 
1               5                   


<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 18
Cys Ala Gly Gly Leu Leu Thr Met Val 
1               5                   


<210> 19
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 19
Cys Leu Ala Gly Leu Leu Thr Met Val 
1               5                   


<210> 20
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 20
Cys Leu Gly Ala Leu Leu Thr Met Val 
1               5                   


<210> 21
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 21
Cys Leu Gly Gly Ala Leu Thr Met Val 
1               5                   


<210> 22
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 22
Cys Leu Gly Gly Leu Ala Thr Met Val 
1               5                   


<210> 23
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 23
Cys Leu Gly Gly Leu Leu Ala Met Val 
1               5                   


<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 24
Cys Leu Gly Gly Leu Leu Thr Ala Val 
1               5                   


<210> 25
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 25
Cys Leu Gly Gly Leu Leu Thr Met Ala 
1               5                   


<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 26
Ser Leu Gly Gly Leu Leu Thr Met Val 
1               5                   


<210> 27
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 27
Cys Leu Gly Gly Leu Ile Thr Met Val 
1               5                   


<210> 28
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 28
Ser Leu Gly Gly Leu Leu Thr Met Ala 
1               5                   


<210> 29
<211> 657
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 29
caggtgcagc tgaagcagtc aggacctggc ctagtgcagc cctcacagag cctgtccatc       60

acctgcacag tctctggttt ctcattaact aactatggtg tacactgggt tcgccagtct      120

ccaggaaagg gtctggagtg gctgggagtg atatggagtg gtggaagcac agactataat      180

gcagctttca tatccagatt gagcatcagc aaggacaatt ccaagagcca agttttcttt      240

aaaatgaaca gtctgcaagc taatgacaca gccatatatt actgtgccag aaattgggtc      300

ccttactact ttgactactg gggccaaggc accactctca cagtctcctc agccaaaacg      360

acacccccat ctgtctatcc actggcccct ggatctgctg cccaaactaa ctccatggtg      420

accctgggat gcctggtcaa gggctatttc cctgagccag tgacagtgac ctggaactct      480

ggatccctgt ccagcggtgt gcacaccttc ccagctgtcc tgcagtctga cctctacact      540

ctgagcagct cagtgactgt cccctccagc acctggccca gcgagaccgt cacctgcaac      600

gttgcccacc cggccagcag caccaaggtg gacaagaaaa ttgtgcccag ggattgt         657


<210> 30
<211> 219
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 30
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asn Trp Val Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu 
        115                 120                 125             


Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys 
    130                 135                 140                 


Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser 
145                 150                 155                 160 


Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 
                165                 170                 175     


Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp 
            180                 185                 190         


Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr 
        195                 200                 205             


Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys 
    210                 215                 


<210> 31
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 31
Gly Phe Ser Leu Thr Asn Tyr Gly 
1               5               


<210> 32
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 32
Ile Trp Ser Gly Gly Ser Thr 
1               5           


<210> 33
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 33
Ala Arg Asn Trp Val Pro Tyr Tyr Phe Asp Tyr Trp 
1               5                   10          


<210> 34
<211> 642
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 34
gacattgtga tgacccagtc tcaaaaattc atgtccacat cagttggaga cagggtcagc       60

gtcacctgca gggccagtca gaatgtgttt actaatgtag cctggtatca acagaaacca      120

gggcaagctc ctaaagcact gatttactcg acatcctacc ggtacagtgg agtccctgat      180

cgcttcacag gcagtggatc tgggacagat ttcactctca ccatcagcaa tgtgcagtct      240

gaagacttgg cagagtattt ctgtcagcaa tatatcagct atcctctcac gttcggtgct      300

gggaccaagc tggagctgaa acgggctgat gctgcaccaa ctgtatccat cttcccacca      360

tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac      420

cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgtcctg      480

aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcacg      540

ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca      600

tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gt                         642    


<210> 35
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 35
Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Arg Ala Ser Gln Asn Val Phe Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Thr Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Ile Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala 
            100                 105                 110         


Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly 
        115                 120                 125             


Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile 
    130                 135                 140                 


Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu 
145                 150                 155                 160 


Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr 
            180                 185                 190         


Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser 
        195                 200                 205             


Phe Asn Arg Asn Glu Cys 
    210                 


<210> 36
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 36
Gln Asn Val Phe Thr Asn 
1               5       


<210> 37
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 37
Ser Thr Ser 
1           


<210> 38
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 38
Gln Gln Tyr Ile Ser Tyr Pro Leu Thr Phe 
1               5                   10  


<210> 39
<211> 8
<212> PRT
<213> Cytomegalovirus

<400> 39
Val Leu Ala Glu Leu Val Lys Gln 
1               5                   



